Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by SanFrancisco99on Apr 17, 2015 2:43pm

197 Views

Post# 23641598

RE:RE:RE:when you have an infestestation...

Hi Fouremm:

Excellent post - thank you.

You peaked my interest on one item in particular, as follows: "In the seeking Alpha article Norman Wong's response to BC's questions would indicate this."

That's something I don't think I have seen - Norman Wong answering some questions posed by BC. Can you tell me where I can find that?

Thank you in advance for any help you can offer. I

Bullboard Posts

Dynamic Funds Launches new ETF series on the TSX